Yumanity Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
YMTX Nasdaq 8731 https://www.yumanity.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Yumanity Therapeutics Inc

Yumanity Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Developments - May 12th, 2022 8:45 pm
Yumanity Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Developments - Mar 24th, 2022 8:15 pm
Yumanity cuts staff by 60%, considers a sale - Feb 18th, 2022 5:16 pm
Yumanity Therapeutics Exploring Strategic Alternatives to Enhance Shareholder Value and Announces Restructuring - Feb 17th, 2022 1:30 pm
Yumanity Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 4th, 2022 11:48 pm
Yumanity Reports Partial Clinical Hold by U.S. FDA on Multidose Clinical Trials for YTX-7739 - Jan 19th, 2022 12:30 pm
Yumanity’s Approach to Neurodegenerative Diseases Validated by Two External Collaborations - Jan 11th, 2022 1:00 pm
Yumanity Therapeutics to Present at the H.C. Wainwright BioConnect Conference - Jan 4th, 2022 1:00 pm
Yumanity Therapeutics to Present at Multiple Upcoming November Investor Conferences - Nov 16th, 2021 9:30 pm
Yumanity Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Developments - Nov 15th, 2021 12:30 pm
Yumanity Therapeutics Announces Positive Top-Line Results of Phase 1b Clinical Trial for YTX-7739 in Patients with Parkinson’s Disease; Company Plans to Advance Program to Phase 2 - Nov 10th, 2021 12:00 pm
Yumanity Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Sep 9th, 2021 8:15 pm
Yumanity Therapeutics to Present at the H.C. Wainwright 23rd Global Investment Conference - Sep 9th, 2021 12:00 pm
Yumanity Therapeutics Appoints Michael D. Wyzga as Chief Financial Officer and Announces Inducement Grants - Aug 16th, 2021 11:00 am
Yumanity Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate Developments - Aug 12th, 2021 8:15 pm
Yumanity Therapeutics to Present at the BTIG Virtual Biotechnology Conference - Aug 6th, 2021 11:00 am
Yumanity Therapeutics Appoints Devin W. Smith as General Counsel - Jun 14th, 2021 11:00 am
Yumanity Therapeutics to Present at Upcoming Virtual Investor Conferences - May 27th, 2021 11:00 am